Patients who achieved HIV virologic suppression tended to be older and were more likely to report continued engagement in HIV care than those with persistent viremia.

A new long-acting medicine that could make preventing HIV transition might soon be even for poor countries like Uganda thanks to agreements between producers and key HIV/AIDS prevention programme ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating-and possibly even ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even ...

Being out of care doesn’t have to be permanent, and many people can restart HIV treatment. The sooner PWH restart treatment, ...

The number of people living with HIV in Bulawayo has declined from 79 711 in 2020 to 76 608 in 2024, as new infections continue to fall in response to significant progress in prevention and treatment.

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. A daughter's search for healing brought to life through Wish of a ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Research published in The Lancet HIV earlier this year, experts estimated that, if purchased at scale, the cost of generic lenacapavir could range from USD 35 to USD 46 per person-year. Falling to USD ...

Persistent symptoms after treatment, sometimes called persistent Lyme disease (PLD) or Post Treatment Lyme Disease Syndrome ...